Eris Lifesciences Limited — Important, 06-03-2025: Updates

As part of its internal restructuring, Eris Lifesciences has transferred 100% of its holdings in Eris Oaknet Healthcare Private Limited and Aprica Healthcare Limited to its wholly-owned subsidiary, Eris Therapeutics Limited. For the last financial year, Aprica Healthcare contributed a total revenue of ₹604.05 million and a net worth of ₹805.75 million, while Eris Oaknet's total revenue was ₹726.47 million with a net worth of ₹633.33 million. The total consideration from the sale amounts to ₹8619.14 million, with the transaction classified as a related party transaction conducted at arm's length. The agreement for the sale was finalized with an expected completion date by the end of March 2025. This strategic move could enhance Eris Lifesciences’ operational focus and improve its financial position.